Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
|Videos|April 1, 2022
What's Happening in the Vitiligo Pipeline?
Author(s)Linda Stocum, Associate Editor
In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.
Advertisement
Pearl Grimes, MD, FAAD, a Dermatology Times® board member, and Seemal R. Desai, MD, FAAD, highlight the vitiligo pipeline.
The topic of the potential treatment ruxolitinib (Opzelura; Incyte), which the FDA granted Priority Review and has a Prescription Drug User Fee Act (PDUFA) target action date is April 18, 2022, as the first FDA approved therapy for vitiligo is brought up along with the costs of this treatment. Watch the full discussion below.
Advertisement
Related to this article
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.
The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
Don't Be Rash: Building the Pediatric Psoriasis Treatment Ladder
4
Alopecia Awareness Month: Supporting Patients Beyond the Treatment Plan
5